Metabolomics is an emerging field of science that performs systematic quantification and classification of metabolites in a biological system by using sophisticated analytical technologies. The analytical techniques used include spectroscopy, chromatography, and multivariate analysis. The global metabolomics market accounted for $1,379 million in 2016, and is estimated to reach $3,301 million by 2023, registering a CAGR of 13.2% from 2017 to 2023.
The global metabolomics market is driven by continues technological advancements in medical devices and adoption of metabolomics in precision medicine. Moreover, increased private & government funding for metabolomics R&D activities is expected to propel the market growth during the forecast period. However, high cost of analytical equipment & maintenance and lack of effective data management for metabolomics profiling are expected to hamper the market growth.
The global metabolomics market is segmented based on product & service, application, indication, and geography. Based on the product & service, it is categorized into metabolomics instruments and metabolomics bioinformatics tools & services. The metabolomics instruments segment is further divided into separation techniques and detection techniques. The separation techniques segment is further classified into high-performance liquid chromatography, gas chromatography, ultra-performance liquid chromatography, and capillary electrophoresis. The detection techniques segment is further categorized into mass spectrometry, nuclear magnetic resonance spectroscopy, and surface-based mass analysis. The metabolomics bioinformatics tools & services segment is further divided into bioinformatics tools & databases and bioinformatics services. Based on application, the market is categorized into biomarker discovery, drug discovery, toxicology testing, nutrigenomics, functional genomics, personalized medicine, and others. Based on indication, it is divided into cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, and others. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the global metabolomics market along with the current trends and future estimations to elucidate the imminent investment pockets.
The report presents quantitative analysis of the market from 2016 to 2023 to enable stakeholders capitalize on the prevailing market opportunities.
Extensive analysis of the market based on product & service assists in understanding the key trends in the industry.
Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Product & Service
Metabolomics Instruments
Separation Techniques
High-performance Liquid Chromatography
Gas Chromatography
Ultra-performance Liquid Chromatography
Capillary Electrophoresis.
Detection Techniques
Mass Spectrometry
Nuclear Magnetic Resonance Spectroscopy
Surface-based Mass Analysis
Metabolomics Bioinformatics Tools & Services
Bioinformatics Tools
Databases and Bioinformatics Services
By Application
Biomarker Discovery
Drug Discovery
Toxicology Testing
Nutrigenomics
Functional Genomics
Personalized Medicine
Others
By Indication
Cancer
Cardiovascular Disorders
Neurological Disorders
Inborn Errors of Metabolism
Others
BY GEOGRAPHY
North America
U.S.
Canada
Mexico
Europe
France
Germany
UK
Italy
Spain
The Netherlands
Norway
Russia
Sweden
Switzerland
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
New Zealand
Taiwan
Thailand
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Chile
Columbia
Egypt
Iran
Israel
Turkey
Venezuela
Rest of LAMEA
KEY PLAYERS PROFILED
Agilent Technologies, Inc.
Danaher Corporation
Biocrates Life Sciences AG
Bruker Corporation
Leco Corporation
Metabolon, Inc.
Human Metabolome Technologies, Inc.
Bio-Rad Laboratories, Inc.
Shimadzu Corporation
Waters Corporation
Thermo Fisher Scientific Inc.
The other players operating in the mass spectrometry market include (companies not profiled in the report):
Kore Technologies, Ltd.
Dani Instruments S.P.A.
Perkinelmer, Inc.
Evans Analytical Group LLC.
'
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. TOP PLAYER POSITIONING
3.4. PORTERS FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
CHAPTER 4 GLOBAL METABOLOMICS MARKET, BY PRODUCT & SERVICE
4.1. OVERVIEW
4.1.1. Market size & forecast
4.2. METABOLOMICS INSTRUMENTS
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size & forecast
4.2.4. Separation tools
4.2.4.1. High-Performance Liquid Chromatography
4.2.4.1.1. Market size & forecast
4.2.4.2. Gas Chromatography
4.2.4.2.1. Market size & forecast
4.2.4.3. Ultra-Performance Liquid Chromatography
4.2.4.3.1. Market size & forecast
4.2.4.4. Capillary Electrophoresis
4.2.4.4.1. Market size & forecast
4.2.5. detection tools
4.2.5.1. Mass Spectrometry
4.2.5.1.1. Market size & forecast
4.2.5.2. Nuclear Magnetic Resonance Spectroscopy
4.2.5.2.1. Market size & forecast
4.2.5.3. Surface-Based Mass Analysis
4.2.5.3.1. Market size & forecast
4.3. METABOLOMICS BIOINFORMATICS TOOLS AND SERVICES
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size & forecast
4.3.4. Bioinformatics Tools
4.3.4.1. Market size & forecast
4.3.5. Databases and Bioinformatics Services
4.3.5.1. Market size & forecast
CHAPTER 5 GLOBAL METABOLOMICS MARKET, BY APPLICATION
5.1. OVERVIEW
5.1.1. Market size & forecast
5.2. BIOMARKER DISCOVERY
5.2.1. Market size & forecast
5.3. DRUG DISCOVERY
5.3.1. Market size & forecast
5.4. TOXICOLOGY TESTING
5.4.1. Market size & forecast
5.5. NUTRIGENOMICS
5.5.1. Market size & forecast
5.6. FUNCTIONAL GENOMICS
5.6.1. Market size & forecast
5.7. PERSONALIZED MEDICINE
5.7.1. Market size & forecast
5.8. OTHER APPLICATION
5.8.1. Market size & forecast
CHAPTER 6 GLOBAL METABOLOMICS MARKET, BY INDICATION
6.1. OVERVIEW
6.1.1. Market size & forecast
6.2. CANCER
6.2.1. Market size & forecast
6.3. CARDIOVASCULAR DISORDERS
6.3.1. Market size & forecast
6.4. NEUROLOGICAL DISORDERS
6.4.1. Market size & forecast
6.5. INBORN ERRORS OF METABOLISM
6.5.1. Market size & forecast
6.6. OTHER INDIACTIONS
6.6.1. Market size & forecast
CHAPTER 7 GLOBAL METABOLOMICS MARKET, BY GEOGRAPHY
7.1. OVERVIEW
7.2. NORTH AMERICA
7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size & forecast
7.2.4. Market size & forecast
7.2.4.1. U.S. market size and forecast
7.2.4.2. Canada market size and forecast
7.2.4.3. Mexico market size and forecast
7.3. EUROPE
7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size & forecast
7.3.4. Market size & forecast
7.3.4.1. Germany market size and forecast
7.3.4.2. France market size and forecast
7.3.4.3. UK market size and forecast
7.3.4.4. Italy market size and forecast
7.3.4.5. Spain market size and forecast
7.3.4.6. Rest of Europe market size and forecast
7.4. ASIA-PACIFIC
7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size & forecast
7.4.4. Market size & forecast
7.4.4.1. Japan market size and forecast
7.4.4.2. China market size and forecast
7.4.4.3. Australia market size and forecast
7.4.4.4. India market size and forecast
7.4.4.5. South Korea market size and forecast
7.4.4.6. Taiwan market size and forecast
7.4.4.7. Rest of Asia-Pacific market size and forecast
7.5. LAMEA
7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size & forecast
7.5.4. Market size & forecast
7.5.4.1. Brazil market size and forecast
7.5.4.2. Turkey market size and forecast
7.5.4.3. Saudi Arabia market size and forecast
7.5.4.4. South Africa market size and forecast
7.5.4.5. Rest of LAMEA market size and forecast
CHAPTER 8 COMPANY PROFILES
8.1. AGILENT TECHNOLOGIES, INC.
8.1.1. Operating business segments
8.1.2. Business performance
8.2. DANAHER CORPORATION
8.2.1. Operating business segments
8.2.2. Business performance
8.2.3. Key strategic moves and developments
8.3. BIOCRATES LIFE SCIENCES AG
8.3.1. Operating business segments
8.3.2. Business performance
8.3.3. Key strategic moves and developments
8.4. BRUKER CORPORATION
8.4.1. Operating business segments
8.4.2. Business performance
8.4.3. Key strategic moves and developments
8.5. LECO CORPORATION
8.5.1. Operating business segments
8.5.2. Business performance
8.5.3. Key strategic moves and developments
8.6. METABOLON, INC.
8.6.1. Operating business segments
8.6.2. Business performance
8.6.3. Key strategic moves and developments
8.7. HUMAN METABOLOME TECHNOLOGIES, INC.
8.7.1. Operating business segments
8.7.2. Business performance
8.7.3. Key strategic moves and developments
8.8. BIO-RAD LABORATORIES, INC.
8.8.1. Operating business segments
8.8.2. Business performance
8.8.3. Key strategic moves and developments
8.9. SHIMADZU CORPORATION
8.9.1. Operating business segments
8.9.2. Business performance
8.9.3. Key strategic moves and developments
8.10. WATERS CORPORATION
8.10.1. Operating business segments
8.10.2. Business performance
8.10.3. Key strategic moves and developments
